Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

[18F]tetrafluoroborate-PET/CT enables sensitive tumor and metastasis in vivo imaging in a sodium iodide symporter-expressing tumor model.

Diocou S, Volpe A, Jauregui-Osoro M, Boudjemeline M, Chuamsaamarkkee K, Man F, Blower PJ, Ng T, Mullen GED, Fruhwirth GO.

Sci Rep. 2017 Apr 19;7(1):946. doi: 10.1038/s41598-017-01044-4.

2.

Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.

Schmohl KA, Gupta A, Grünwald GK, Trajkovic-Arsic M, Klutz K, Braren R, Schwaiger M, Nelson PJ, Ogris M, Wagner E, Siveke JT, Spitzweg C.

Oncotarget. 2017 May 16;8(20):33393-33404. doi: 10.18632/oncotarget.16499.

3.

Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery.

Müller AM, Schmohl KA, Knoop K, Schug C, Urnauer S, Hagenhoff A, Clevert DA, Ingrisch M, Niess H, Carlsen J, Zach C, Wagner E, Bartenstein P, Nelson PJ, Spitzweg C.

Oncotarget. 2016 Aug 23;7(34):54795-54810. doi: 10.18632/oncotarget.10758.

4.

Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene.

Urnauer S, Morys S, Krhac Levacic A, Müller AM, Schug C, Schmohl KA, Schwenk N, Zach C, Carlsen J, Bartenstein P, Wagner E, Spitzweg C.

Mol Ther. 2016 Aug;24(8):1395-404. doi: 10.1038/mt.2016.95. Epub 2016 May 9.

5.

Establishment of an Effective Radioiodide Thyroid Ablation Protocol in Mice.

Schmohl KA, Müller AM, Schwenk N, Knoop K, Rijntjes E, Köhrle J, Heuer H, Bartenstein P, Göke B, Nelson PJ, Spitzweg C.

Eur Thyroid J. 2015 Sep;4(Suppl 1):74-80. doi: 10.1159/000381019. Epub 2015 May 23.

6.

Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer.

Micali S, Bulotta S, Puppin C, Territo A, Navarra M, Bianchi G, Damante G, Filetti S, Russo D.

BMC Cancer. 2014 Apr 30;14:303. doi: 10.1186/1471-2407-14-303. Review.

7.

The Na+/I- symporter (NIS): mechanism and medical impact.

Portulano C, Paroder-Belenitsky M, Carrasco N.

Endocr Rev. 2014 Feb;35(1):106-49. doi: 10.1210/er.2012-1036. Epub 2013 Dec 4. Review.

8.

Objective assessment of image quality VI: imaging in radiation therapy.

Barrett HH, Kupinski MA, Müeller S, Halpern HJ, Morris JC 3rd, Dwyer R.

Phys Med Biol. 2013 Nov 21;58(22):8197-213.

9.

Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma.

Knoop K, Schwenk N, Dolp P, Willhauck MJ, Zischek C, Zach C, Hacker M, Göke B, Wagner E, Nelson PJ, Spitzweg C.

Hum Gene Ther. 2013 Mar;24(3):306-16. doi: 10.1089/hum.2012.104.

10.

Systemic TNFα gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer.

Su B, Cengizeroglu A, Farkasova K, Viola JR, Anton M, Ellwart JW, Haase R, Wagner E, Ogris M.

Mol Ther. 2013 Feb;21(2):300-8. doi: 10.1038/mt.2012.229. Epub 2012 Nov 13.

11.

Efficient multicistronic co-expression of hNIS and hTPO in prostate cancer cells for nonthyroidal tumor radioiodine therapy.

Li G, Xiang L, Yang W, Wang Z, Wang J, Chen K.

Am J Nucl Med Mol Imaging. 2012;2(4):483-98. Epub 2012 Oct 15.

12.

Nanomedicine: a primer for surgeons.

Wong KK, Liu XL.

Pediatr Surg Int. 2012 Oct;28(10):943-51. Epub 2012 Aug 15. Review.

13.

The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Kogai T, Brent GA.

Pharmacol Ther. 2012 Sep;135(3):355-70. doi: 10.1016/j.pharmthera.2012.06.007. Epub 2012 Jun 29. Review.

14.

Normalisation to blood activity is required for the accurate quantification of Na/I symporter ectopic expression by SPECT/CT in individual subjects.

Richard-Fiardo P, Franken PR, Lamit A, Marsault R, Guglielmi J, Cambien B, Graslin F, Lindenthal S, Darcourt J, Pourcher T, Vassaux G.

PLoS One. 2012;7(3):e34086. doi: 10.1371/journal.pone.0034086. Epub 2012 Mar 21.

15.

Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.

Klutz K, Willhauck MJ, Dohmen C, Wunderlich N, Knoop K, Zach C, Senekowitsch-Schmidtke R, Gildehaus FJ, Ziegler S, Fürst S, Göke B, Wagner E, Ogris M, Spitzweg C.

Hum Gene Ther. 2011 Dec;22(12):1563-74. doi: 10.1089/hum.2011.041. Epub 2011 Oct 11.

16.

Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery.

Knoop K, Kolokythas M, Klutz K, Willhauck MJ, Wunderlich N, Draganovici D, Zach C, Gildehaus FJ, Böning G, Göke B, Wagner E, Nelson PJ, Spitzweg C.

Mol Ther. 2011 Sep;19(9):1704-13. doi: 10.1038/mt.2011.93. Epub 2011 May 17.

17.

Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.

Klutz K, Schaffert D, Willhauck MJ, Grünwald GK, Haase R, Wunderlich N, Zach C, Gildehaus FJ, Senekowitsch-Schmidtke R, Göke B, Wagner E, Ogris M, Spitzweg C.

Mol Ther. 2011 Apr;19(4):676-85. doi: 10.1038/mt.2010.296. Epub 2011 Jan 18.

18.

Genetics and phenomics of hypothyroidism and goiter due to NIS mutations.

Spitzweg C, Morris JC.

Mol Cell Endocrinol. 2010 Jun 30;322(1-2):56-63. doi: 10.1016/j.mce.2010.02.007. Epub 2010 Feb 12. Review.

Supplemental Content

Support Center